Physician profile
Frederick Smith
NPI 1730185935
$158,698.27
in general payments reported to CMS, 2019-2025
85 companies · $7,754 in 2025
The $7,754 reported for 2025 was more than what 78% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $11K · 2021: $20K · 2022: $66K · 2023: $18K · 2024: $9,408 · 2025: $7,754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $15K · Consulting Fee: $3,140 · Long Term Medical Supply Or Device Loan: $1,530 · Travel and Lodging: $1,317 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,690.00 |
| Food and Beverage | $14,507.28 |
| Consulting Fee | $3,140.00 |
| Long Term Medical Supply Or Device Loan | $1,529.72 |
| Travel and Lodging | $1,317.26 |
| Education | $133.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $60,791.96 | 2019-2025 | Lynparza, Imfinzi, Calquence |
| Merck Sharp & Dohme LLC | $49,206.16 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Daiichi Sankyo INC. | $6,074.75 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Clovis Oncology, INC. | $5,550.15 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $4,400.33 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $3,691.14 | 2019-2025 | Alunbrig, Fruzaqla, Ninlaro |
| Pfizer INC. | $2,795.81 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,935.54 | 2019-2025 | |
| Janssen Biotech, INC. | $1,712.86 | 2019-2025 | Darzalex, Talvey, Rybrevant |
| Bayer Healthcare Pharmaceuticals INC. | $1,665.54 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,632.46 | 2019-2025 | Opdivo, Krazati, Eliquis |
| Lilly USA, LLC | $1,158.01 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Genentech USA, INC. | $1,152.79 | 2019-2025 | Polivy, Lunsumio, Venclexta |
| Genzyme Corporation | $1,150.23 | 2019-2025 | |
| Seagen INC. | $870.56 | 2020-2023 | Tukysa, Adcetris |
Show all 85 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $834.85 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Celgene Corporation | $775.39 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Amgen INC. | $750.32 | 2019-2023 | Lumakras, Blincyto, Kyprolis |
| Eisai INC. | $597.13 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $580.18 | 2020-2025 | Libtayo, Lynozyfic |
| Astellas Pharma US INC | $561.39 | 2019-2025 | Padcev, Xtandi, Vyloy |
| Emd Serono, INC. | $498.13 | 2019-2025 | |
| Array Biopharma INC | $455.46 | 2020-2025 | Braftovi, Mektovi, Lorbrena |
| Pharmacyclics LLC, An Abbvie Company | $445.94 | 2019-2023 | Imbruvica, Epkinly |
| Exelixis INC. | $444.31 | 2019-2025 | Cabometyx |
| Sun Pharmaceutical Industries INC. | $415.57 | 2019-2023 | |
| Ipsen Biopharmaceuticals, INC | $411.29 | 2019-2024 | Onivyde, Somatuline Depot, Tazverik |
| Taiho Oncology, INC. | $401.69 | 2019-2025 | |
| Pharmacosmos Therapeutics INC. | $393.53 | 2021-2025 | Monoferric, Cosela |
| Glaxosmithkline, LLC. | $382.58 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Tersera Therapeutics LLC | $370.79 | 2019-2025 | Xermelo, Zoladex |
| Abbvie INC. | $351.60 | 2019-2025 | Creon, Venclexta |
| Puma Biotechnology, INC. | $342.61 | 2019-2025 | |
| Pharmaessentia USA Corporation | $338.73 | 2022-2025 | Besremi |
| Blueprint Medicines Corporation | $300.51 | 2020-2025 | Ayvakit |
| Rigel Pharmaceuticals, INC. | $288.21 | 2019-2024 | Rezlidhia, Tavalisse |
| Gilead Sciences, INC. | $270.53 | 2019-2024 | Trodelvy |
| Coherus Oncology, INC. | $253.88 | 2021-2025 | Udenyca |
| Secura Bio, INC. | $250.00 | 2021 | |
| Myriad Genetic Laboratories, INC. | $244.24 | 2020-2025 | Precisetumor, Mychoice Cdx, Myrisk |
| Beigene USA, INC. | $237.32 | 2020-2025 | Brukinsa, Tevimbra |
| Adaptive Biotechnologies Corporation | $220.82 | 2022-2025 | Clonoseq |
| Karyopharm Therapeutics INC. | $215.06 | 2020-2025 | Xpovio |
| Kite Pharma, INC. | $190.13 | 2020-2025 | Yescarta |
| Foundation Medicine, INC. | $181.98 | 2019-2022 | |
| Stemline Therapeutics INC. | $169.12 | 2023-2025 | Orserdu |
| Spectrum Pharmaceuticals INC. | $161.57 | 2019-2025 | Rolvedon |
| Acrotech Biopharma INC. | $158.58 | 2022-2025 | Beleodaq |
| Morphosys, US INC. | $156.01 | 2021-2024 | Monjuvi |
| Alexion Pharmaceuticals, INC. | $148.09 | 2019-2024 | Ultomiris |
| Aveo Pharmaceuticals, INC. | $124.48 | 2022-2025 | Fotivda |
| Genmab U.S., INC. | $122.71 | 2023-2025 | Epkinly |
| Eusa Pharma (US) LLC | $120.23 | 2020-2022 | |
| Geron Corporation | $116.02 | 2025 | Rytelo |
| Adc Therapeutics America, INC. | $99.26 | 2022-2025 | |
| Mirati Therapeutics, INC. | $97.70 | 2023-2024 | Krazati |
| Ge Healthcare | $92.82 | 2021 | |
| Kyowa Kirin, INC. | $86.96 | 2023-2025 | Poteligeo |
| Sobi, INC | $85.69 | 2022-2025 | |
| Beone Medicines USA, INC. | $82.63 | 2025 | Brukinsa, Tevimbra |
| Cti Biopharma Corp. | $79.42 | 2022-2023 | Vonjo |
| Tactile Systems Technology INC | $77.20 | 2019-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Janssen Scientific Affairs, LLC | $73.94 | 2019 | |
| Dendreon Pharmaceuticals LLC | $73.57 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $71.61 | 2019-2020 | |
| Myovant Sciences INC. | $70.24 | 2021-2022 | |
| Agios Pharmaceuticals, INC. | $66.67 | 2019-2021 | |
| Heron Therapeutics, INC. | $59.00 | 2019-2023 | Sustol |
| G1 Therapeutics, INC. | $48.39 | 2022-2023 | Cosela |
| Janssen Pharmaceuticals, INC | $47.10 | 2019-2024 | Xarelto |
| Springworks Therapeutics, INC. | $44.88 | 2024-2025 | Ogsiveo |
| Partner Therapeutics, INC. | $44.72 | 2019-2020 | |
| Epizyme, INC. | $44.37 | 2021-2023 | |
| Deciphera Pharmaceuticals INC. | $42.62 | 2021 | |
| Recordati_rare_diseases_inc. | $33.25 | 2024-2025 | Sylvant |
| Tesaro, INC. | $25.53 | 2019 | |
| Global Blood Therapeutics, INC. | $24.56 | 2022 | |
| Jazz Pharmaceuticals INC. | $22.98 | 2019 | |
| Azurity Pharmaceuticals, INC. | $22.08 | 2025 | Danziten |
| Blue Earth Diagnostics | $22.01 | 2021 | |
| Servier Pharmaceuticals LLC | $21.03 | 2021 | |
| Tg Therapeutics, INC. | $20.91 | 2021 | |
| Mylan Institutional INC. | $17.70 | 2020 | |
| Amag Pharmaceuticals, INC. | $16.70 | 2022 | |
| Sumitomo Pharma America, INC. | $13.46 | 2023 | Orgovyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$36,164.48 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.